Orgenesis and Pall Corporation Receive $800,000 Grant From BIRD Foundation for Diabetes Research and Development
Marketwired - Mon Jan 26, 7:49AM CST
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that Orgenesis and Pall Corporation have received an $800,000 grant from the Israel-U.S. Binational Industrial Research and Development ("BIRD"
PLL: 103.00 (+0.14)
Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in Europe
Marketwired - Mon Nov 24, 2:21PM CST
Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DG06) for a EUR 2,015 million support program for the research and development of a potential cure for Type 1 Diabetes.
Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes
Marketwired - Wed Oct 15, 6:01AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received a patent for the technology supporting its unique cell-based therapy, which is being developed as a potential cure for Type 1 Diabetes. The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah Ferber and the research team at Orgenesis who have used the technology to successfully reprogram human liver cells into glucose-responsive, fully functional Insulin Producing Cells (IPCs).
Scott Carmer Named as CEO of Orgenesis North America
Marketwire - Mon Aug 04, 8:03AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, today announced the appointment of industry veteran Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies.
Orgenesis Signs Agreement With MaSTherCell to Scale Manufacturing of Insulin-Producing Liver Cells to Combat Diabetes
Marketwire - Mon Jul 07, 7:40AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine today announced that its Belgian subsidiary, Orgenesis SPRL, has signed a strategic agreement with MaSTherCell SA of Gosselies, Belgium. Orgenesis believes that the agreement will enable Orgenesis to advance its manufacturing (GMP) process from lab scale to clinical scale as it prepares for Phase I and Phase II clinical trials.
Orgenesis Receives $1.5 Million Term Loan to Help Fund Breakthrough Innovation in Diabetes Research
Marketwire - Wed Jun 25, 7:31AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, announced today that it raised $1.5 million via a senior secured term loan facility.